Abstract | BACKGROUND: METHODS: Pubmed was searched for all published case-control studies about MTHFR polymorphisms and prostate cancer risk. RESULTS: In all, 13 studies including 5872 cases and 6255 controls described C677T genotypes, among which 9 articles, containing 2847 cases and 3657 controls described A1298C genotypes, were involved in our meta-analysis. Odds ratios ( ORs) with 95% confidence intervals (CIs) were estimated to assess the association between MTHFR polymorphisms and prostate cancer risk, heterogeneity, publication bias and sensitivity were also calculated. Overall, meta-analysis indicated that the 677T allele was more likely to exert protective effect on prostate cancer risk (random-effects pooled OR, 0.78 (0.64-0.96); P=0.016 (P=0.033 for heterogeneity studies)) in a recessive genetic model, no associations were found in other genetic models or in comparing a/a versus A/A homozygous. Neither did we find any difference in effects on high or low aggressive prostate cancer. No evidence of an association of MTHFR A1298C polymorphism with prostate cancer was found. CONCLUSIONS: C677T of the MTHFR gene may provide protective effects on susceptibility to prostate cancer risk.
|
Authors | X-L Li, J-H Xu |
Journal | Prostate cancer and prostatic diseases
(Prostate Cancer Prostatic Dis)
Vol. 15
Issue 3
Pg. 244-9
(Sep 2012)
ISSN: 1476-5608 [Electronic] England |
PMID | 22370724
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- MTHFR protein, human
- Methylenetetrahydrofolate Reductase (NADPH2)
|
Topics |
- Case-Control Studies
- Genetic Predisposition to Disease
- Genotype
- Humans
- Inheritance Patterns
- Male
- Methylenetetrahydrofolate Reductase (NADPH2)
(genetics)
- Odds Ratio
- Polymorphism, Single Nucleotide
- Prostatic Neoplasms
(genetics)
- Risk
|